| Assay Name | Tissue | Organism | Target Gene ID | Target HGNC Symbol | Response | AC50 Value |
|---|
| CCTE_Deisenroth_AIME_384WELL_LUC_Active | Mammary gland/breast | Human | 2099 | ESR1 | Gain | 6.67 μM |
| CCTE_Deisenroth_AIME_384WELL_LUC_Inactive | Mammary gland/breast | Human | 2099 | ESR1 | Gain | 6.69 μM |
| HCAN_AUR_hTPO | Kidney | Human | 7173 | TPO | Loss | 0.77 μM |
| ATG_ERE_CIS | Liver | Human | 2099 | ESR1 | Inhibitory | 0.84 μM |
| ATG_HSE_CIS | Liver | Human | 3297 | HSF1 | Inhibitory | 45.65 μM |
| ATG_ISRE_CIS | Liver | Human | 3659 | IRF1 | Activatory | 100.0 μM |
| ATG_NRF1_CIS | Liver | Human | 4899 | NRF1 | Activatory | 43.16 μM |
| ATG_TCF_b_cat_CIS | Liver | Human | 6932|6934|51176|83439 | TCF7|TCF7L2|LEF1|TCF7L1 | Inhibitory | 47.94 μM |
| ATG_ERa_TRANS | Liver | Human | 2099 | ESR1 | Gain | 1.58 μM |
| ATG_PPARg_TRANS | Liver | Human | 5468 | PPARG | Gain | 31.72 μM |
| ATG_ERE_CIS | Liver | Human | 2099 | ESR1 | Activatory | 0.62 μM |
| ATG_HSE_CIS | Liver | Human | 3297 | HSF1 | Activatory | 42.25 μM |
| ATG_PPRE_CIS | Liver | Human | 5465|5467|5468 | PPARA|PPARD|PPARG | Activatory | 39.24 μM |
| ATG_ERa_TRANS | Liver | Human | 2099 | ESR1 | Gain | 0.63 μM |
| ATG_PPARg_TRANS | Liver | Human | 5468 | PPARG | Gain | 50.57 μM |
| ATG_ERE_CIS | Liver | Human | 2099 | ESR1 | Inhibitory | 0.65 μM |
| ATG_HSE_CIS | Liver | Human | 3297 | HSF1 | Inhibitory | 53.36 μM |
| ATG_ERa_TRANS | Liver | Human | 2099 | ESR1 | Gain | 0.58 μM |
| ATG_PPARg_TRANS | Liver | Human | 5468 | PPARG | Gain | 31.98 μM |
| NVS_ADME_hCYP19A1 | | Human | 1588 | CYP19A1 | Loss | 6.24 μM |
| NVS_ENZ_hCK1D | | Human | 1453 | CSNK1D | Loss | 12.58 μM |
| NVS_NR_hER | | Human | 2099 | ESR1 | Loss | 0.06 μM |
| NVS_NR_hGR | | Human | 2908 | NR3C1 | Loss | 12.19 μM |
| NVS_NR_hRARa_Agonist | | Human | 5914 | RARA | Gain | 33.36 μM |
| NVS_NR_mERa | | Mouse | 13982 | Esr1 | Loss | 1.69 μM |
| NVS_NR_rAR | Prostate | Rat | 24208 | Ar | Loss | 6.84 μM |
| NVS_ADME_hCYP19A1 | | Human | 1588 | CYP19A1 | Loss | 4.76 μM |
| NVS_NR_hGR | | Human | 2908 | NR3C1 | Loss | 5.65 μM |
| NVS_NR_mERa | | Mouse | 13982 | Esr1 | Loss | 0.33 μM |
| NVS_NR_rAR | Prostate | Rat | 24208 | Ar | Loss | 7.71 μM |
| NVS_ADME_hCYP19A1 | | Human | 1588 | CYP19A1 | Loss | 5.05 μM |
| NVS_NR_hGR | | Human | 2908 | NR3C1 | Loss | 10.87 μM |
| NVS_NR_hRARa_Agonist | | Human | 5914 | RARA | Gain | 25.0 μM |
| NVS_NR_rAR | Prostate | Rat | 24208 | Ar | Loss | 5.55 μM |
| ATG_ERE_CIS | Liver | Human | 2099 | ESR1 | Activatory | 0.93 μM |
| ATG_HSE_CIS | Liver | Human | 3297 | HSF1 | Activatory | 39.71 μM |
| ATG_ERa_TRANS | Liver | Human | 2099 | ESR1 | Gain | 0.83 μM |
| ATG_PPARg_TRANS | Liver | Human | 5468 | PPARG | Gain | 48.12 μM |
| BSK_3C_TissueFactor | Vascular | Human | 2152 | F3 | Inhibitory | 29.17 μM |
| BSK_BE3C_HLADR | Lung | Human | 3122 | HLA-DRA | Inhibitory | 31.75 μM |
| BSK_BE3C_IP10 | Lung | Human | 3627 | CXCL10 | Inhibitory | 30.52 μM |
| BSK_BE3C_PAI1 | Lung | Human | 5054 | SERPINE1 | Inhibitory | 34.57 μM |
| BSK_CASM3C_uPAR | Vascular | Human | 5329 | PLAUR | Inhibitory | 21.32 μM |
| BSK_hDFCGF_IP10 | Skin | Human | 3627 | CXCL10 | Inhibitory | 28.09 μM |
| BSK_hDFCGF_MMP1 | Skin | Human | 4312 | MMP1 | Inhibitory | 20.0 μM |
| BSK_hDFCGF_PAI1 | Skin | Human | 5054 | SERPINE1 | Inhibitory | 20.0 μM |
| BSK_KF3CT_MMP9 | Skin | Human | 4318 | MMP9 | Inhibitory | 20.0 μM |
| BSK_SAg_Eselectin | Vascular | Human | 6401 | SELE | Inhibitory | 3.97 μM |
| NVS_ADME_hCYP1A2 | | Human | 1544 | CYP1A2 | Loss | 3.49 μM |
| NVS_ADME_hCYP2B6 | | Human | 1555 | CYP2B6 | Loss | 6.25 μM |
| NVS_ADME_hCYP2C19 | | Human | 1557 | CYP2C19 | Loss | 6.22 μM |
| NVS_ADME_hCYP3A4 | | Human | 1576 | CYP3A4 | Loss | 5.87 μM |
| NVS_ENZ_hAurA | | Human | 6790 | AURKA | Loss | 22.25 μM |
| NVS_ENZ_hCDK2 | | Human | 1017 | CDK2 | Loss | 16.99 μM |
| NVS_ENZ_hCSF1R | | Human | 1436 | CSF1R | Loss | 12.17 μM |
| NVS_ENZ_hEGFR | | Human | 1956 | EGFR | Loss | 25.0 μM |
| NVS_ENZ_hEphA1 | | Human | 2041 | EPHA1 | Loss | 25.0 μM |
| NVS_ENZ_hFGFR1 | | Human | 2260 | FGFR1 | Loss | 25.0 μM |
| NVS_ENZ_hGSK3b | | Human | 2932 | GSK3B | Loss | 25.0 μM |
| NVS_ENZ_hJak2 | | Human | 3717 | JAK2 | Loss | 21.03 μM |
| NVS_ENZ_hMsk1 | | Human | 9252 | RPS6KA5 | Loss | 24.07 μM |
| NVS_ENZ_hPDE5 | | Human | 8654 | PDE5A | Loss | 21.97 μM |
| NVS_ENZ_hSRC | | Human | 6714 | SRC | Loss | 14.99 μM |
| NVS_ENZ_hTrkA | | Human | 4914 | NTRK1 | Loss | 25.0 μM |
| NVS_ENZ_hVEGFR1 | | Human | 2321 | FLT1 | Loss | 25.0 μM |
| NVS_ENZ_rMAOAC | Brain | Rat | 29253 | Maoa | Loss | 4.69 μM |
| NVS_ENZ_rMAOAP | Liver | Rat | 29253 | Maoa | Loss | 0.92 μM |
| NVS_ENZ_rMAOBC | Brain | Rat | 25750 | Maob | Loss | 12.9 μM |
| NVS_GPCR_h5HT6 | | Human | 3362 | HTR6 | Loss | 4.96 μM |
| NVS_GPCR_hOpiate_D1 | | Human | 4985 | OPRD1 | Loss | 18.52 μM |
| NVS_NR_hAR | | Human | 367 | AR | Loss | 1.35 μM |
| NVS_NR_hPPARg | | Human | 5468 | PPARG | Loss | 40.42 μM |
| NVS_NR_hPR | | Human | 5241 | PGR | Loss | 11.25 μM |
| NVS_NR_mERa | | Mouse | 13982 | Esr1 | Loss | 0.41 μM |
| NVS_NR_rAR | Prostate | Rat | 24208 | Ar | Loss | 9.41 μM |
| NVS_ENZ_hFyn | | Human | 2534 | FYN | Loss | 15.12 μM |
| NVS_ENZ_hInsR | | Human | 3643 | INSR | Loss | 19.34 μM |
| NVS_ENZ_hVEGFR2 | | Human | 3791 | KDR | Loss | 4.96 μM |
| NVS_GPCR_hAdoRA1 | Brain | Human | 134 | ADORA1 | Loss | 10.37 μM |
| CCTE_Simmons_AUR_rTPO | Thyroid gland | Rat | 54314 | Tpo | Loss | 0.18 μM |
| ATG_hERa_XSP1 | Liver | Human | 2099 | ESR1 | Gain | 0.64 μM |
| ATG_hERb_XSP1 | Liver | Human | 2100 | ESR2 | Gain | 0.23 μM |
| ATG_hERb_XSP2 | Liver | Human | 2100 | ESR2 | Gain | 1.32 μM |
| ATG_hERa_XSP2 | Liver | Human | 2099 | ESR1 | Gain | 4.0 μM |
| TOX21_AR_BLA_Antagonist_ratio | Kidney | Human | 367 | AR | Loss | 31.43 μM |
| TOX21_ERa_BLA_Agonist_ratio | Kidney | Human | 2099 | ESR1 | Gain | 12.71 μM |
| TOX21_ERa_LUC_VM7_Agonist | Breast | Human | 2099 | ESR1 | Gain | 1.73 μM |
| TOX21_GR_BLA_Antagonist_ratio | Cervix | Human | 2908 | NR3C1 | Loss | 20.48 μM |
| TOX21_TR_LUC_GH3_Antagonist | Pituitary gland | Rat | 7067|7068 | THRA|THRB | Loss | 35.67 μM |
| TOX21_AhR_LUC_Agonist | Liver | Human | 196 | AHR | Gain | 10.88 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 | Breast | Human | 367 | AR | Loss | 3.68 μM |
| TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide | Breast | Human | 367 | AR | Gain | 20.1 μM |
| TOX21_PGC_ERR_LUC_Agonist | Kidney | Human | 2101 | ESRRA | Gain | 37.38 μM |
| TOX21_ERb_BLA_Agonist_ratio | Kidney | Human | 2100 | ESR2 | Gain | 9.75 μM |
| TOX21_PR_BLA_Antagonist_ratio | Kidney | Human | 5241 | PGR | Loss | 10.21 μM |
| TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 | Breast | Human | 2099 | ESR1 | Gain | 9.54 μM |
| TOX21_PXR_LUC_Agonist | Liver | Human | 8856 | NR1I2 | Gain | 53.27 μM |
| TOX21_SBE_BLA_Antagonist_ratio | Kidney | Human | 4086 | SMAD1 | Loss | 54.98 μM |
| TOX21_p450_CYP3A4_Antagonist | | Human | 1576 | CYP3A4 | Loss | 6.64 μM |
| TOX21_p450_CYP2D6_Antagonist | | Human | 1565 | CYP2D6 | Loss | 9.1 μM |
| TOX21_p450_CYP2C19_Antagonist | | Human | 1557 | CYP2C19 | Loss | 32.22 μM |
| TOX21_p450_CYP1A2_Antagonist | | Human | 1544 | CYP1A2 | Loss | 9.97 μM |
| TOX21_ARE_KS_LUC_Agonist | Skin | Human | 4780 | NFE2L2 | Gain | 46.14 μM |
| TOX21_AR_BLA_Antagonist_ratio | Kidney | Human | 367 | AR | Loss | 38.31 μM |
| TOX21_ERa_BLA_Agonist_ratio | Kidney | Human | 2099 | ESR1 | Gain | 22.32 μM |
| TOX21_ERa_LUC_VM7_Agonist | Breast | Human | 2099 | ESR1 | Gain | 6.57 μM |
| TOX21_TR_LUC_GH3_Antagonist | Pituitary gland | Rat | 7067|7068 | THRA|THRB | Loss | 32.03 μM |
| TOX21_AhR_LUC_Agonist | Liver | Human | 196 | AHR | Gain | 15.97 μM |
| TOX21_ERb_BLA_Agonist_ratio | Kidney | Human | 2100 | ESR2 | Gain | 9.87 μM |
| TOX21_PR_BLA_Antagonist_ratio | Kidney | Human | 5241 | PGR | Loss | 11.27 μM |
| TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 | Breast | Human | 2099 | ESR1 | Gain | 8.28 μM |
| TOX21_PR_BLA_Followup_Antagonist_ratio | Kidney | Human | 5241 | PGR | Loss | 58.11 μM |
| TOX21_PR_LUC_Followup_Antagonist | Kidney | Human | 5241 | PGR | Loss | 68.28 μM |
| TOX21_PXR_LUC_Agonist | Liver | Human | 8856 | NR1I2 | Gain | 35.03 μM |
| TOX21_SBE_BLA_Antagonist_ratio | Kidney | Human | 4086 | SMAD1 | Loss | 53.73 μM |
| TOX21_p450_CYP3A4_Antagonist | | Human | 1576 | CYP3A4 | Loss | 9.05 μM |
| TOX21_p450_CYP2D6_Antagonist | | Human | 1565 | CYP2D6 | Loss | 10.43 μM |
| TOX21_p450_CYP2C19_Antagonist | | Human | 1557 | CYP2C19 | Loss | 34.44 μM |
| TOX21_p450_CYP1A2_Antagonist | | Human | 1544 | CYP1A2 | Loss | 11.52 μM |
| TOX21_ARE_KS_LUC_Agonist | Skin | Human | 4780 | NFE2L2 | Gain | 40.25 μM |
| Assay Name | Tissue | Organism | Target Gene ID | Target HGNC Symbol | Response | AC50 Value |
|---|
| UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist | Bone | Human | 367 | AR | Loss | 3.97 μM |
| UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist | Bone | Human | 367 | AR | Loss | 2.13 μM |
| ACEA_ER_80hr | Breast | Human | 2099 | ESR1 | Gain | 0.55 μM |
| ACEA_ER_80hr | Breast | Human | 2099 | ESR1 | Gain | 0.8 μM |
| ACEA_ER_80hr | Breast | Human | 2099 | ESR1 | Gain | 0.76 μM |
| OT_AR_ARSRC1_0480 | Kidney | Human | 367|6714 | AR|SRC | Gain | 9.36 μM |
| OT_AR_ARSRC1_0960 | Kidney | Human | 367|6714 | AR|SRC | Gain | 10.69 μM |
| OT_ER_ERaERa_0480 | Kidney | Human | 2099 | ESR1 | Gain | 6.64 μM |
| OT_ER_ERaERa_1440 | Kidney | Human | 2099 | ESR1 | Gain | 9.91 μM |
| OT_ER_ERaERb_0480 | Kidney | Human | 2099|2100 | ESR1|ESR2 | Gain | 2.14 μM |
| OT_ER_ERaERb_1440 | Kidney | Human | 2099|2100 | ESR1|ESR2 | Gain | 9.09 μM |
| OT_ER_ERbERb_0480 | Kidney | Human | 2100 | ESR2 | Gain | 1.4 μM |
| OT_ER_ERbERb_1440 | Kidney | Human | 2100 | ESR2 | Gain | 2.21 μM |
| OT_ERa_GFPERaERE_0120 | Cervix | Human | 2099 | ESR1 | Gain | 2.67 μM |
| OT_ERa_GFPERaERE_0480 | Cervix | Human | 2099 | ESR1 | Gain | 2.89 μM |
| OT_FXR_FXRSRC1_1440 | Kidney | Human | 6714|9971 | SRC|NR1H4 | Gain | 50.0 μM |
| OT_AR_ARSRC1_0480 | Kidney | Human | 367|6714 | AR|SRC | Gain | 8.01 μM |
| OT_AR_ARSRC1_0960 | Kidney | Human | 367|6714 | AR|SRC | Gain | 9.92 μM |
| OT_ER_ERaERa_0480 | Kidney | Human | 2099 | ESR1 | Gain | 6.26 μM |
| OT_ER_ERaERa_1440 | Kidney | Human | 2099 | ESR1 | Gain | 7.43 μM |
| OT_ER_ERaERb_0480 | Kidney | Human | 2099|2100 | ESR1|ESR2 | Gain | 1.72 μM |
| OT_ER_ERaERb_1440 | Kidney | Human | 2099|2100 | ESR1|ESR2 | Gain | 7.67 μM |
| OT_ER_ERbERb_0480 | Kidney | Human | 2100 | ESR2 | Gain | 1.63 μM |
| OT_ER_ERbERb_1440 | Kidney | Human | 2100 | ESR2 | Gain | 2.02 μM |
| OT_ERa_GFPERaERE_0120 | Cervix | Human | 2099 | ESR1 | Gain | 2.25 μM |
| OT_ERa_GFPERaERE_0480 | Cervix | Human | 2099 | ESR1 | Gain | 2.15 μM |
| OT_FXR_FXRSRC1_1440 | Kidney | Human | 6714|9971 | SRC|NR1H4 | Gain | 28.09 μM |
| OT_AR_ARELUC_AG_1440 | Ovary | Chinese hamster | 367 | AR | Gain | 29.33 μM |
| OT_AR_ARSRC1_0480 | Kidney | Human | 367|6714 | AR|SRC | Gain | 11.03 μM |
| OT_AR_ARSRC1_0960 | Kidney | Human | 367|6714 | AR|SRC | Gain | 9.45 μM |
| OT_ER_ERaERa_0480 | Kidney | Human | 2099 | ESR1 | Gain | 6.81 μM |
| OT_ER_ERaERa_1440 | Kidney | Human | 2099 | ESR1 | Gain | 7.6 μM |
| OT_ER_ERaERb_0480 | Kidney | Human | 2099|2100 | ESR1|ESR2 | Gain | 2.03 μM |
| OT_ER_ERaERb_1440 | Kidney | Human | 2099|2100 | ESR1|ESR2 | Gain | 10.71 μM |
| OT_ER_ERbERb_0480 | Kidney | Human | 2100 | ESR2 | Gain | 1.6 μM |
| OT_ER_ERbERb_1440 | Kidney | Human | 2100 | ESR2 | Gain | 2.09 μM |
| OT_ERa_GFPERaERE_0120 | Cervix | Human | 2099 | ESR1 | Gain | 2.24 μM |
| OT_ERa_GFPERaERE_0480 | Cervix | Human | 2099 | ESR1 | Gain | 2.11 μM |
| OT_AR_ARELUC_AG_1440 | Ovary | Chinese hamster | 367 | AR | Gain | 0.72 μM |
| ACEA_AR_agonist_80hr | Prostate | Human | 367 | AR | Gain | 0.19 μM |
| ACEA_AR_antagonist_80hr | Prostate | Human | 367 | AR | Loss | 26.3 μM |
| TOX21_ARE_BLA_Agonist_ratio | Liver | Human | 4780 | NFE2L2 | Gain | 77.22 μM |
| TOX21_HSE_BLA_Agonist_ratio | Cervix | Human | 3297 | HSF1 | Gain | 63.75 μM |
| TOX21_p53_BLA_p3_ratio | Intestinal | Human | 7157 | TP53 | Gain | 73.34 μM |
| TOX21_p53_BLA_p5_ratio | Intestinal | Human | 7157 | TP53 | Gain | 74.51 μM |
| TOX21_HDAC_LUC_Antagonist | Colon | Human | 3065 | HDAC1 | Loss | 37.77 μM |
| TOX21_SHH_3T3_GLI3_LUC_Antagonist | Embryo | Mouse | 6469 | SHH | Loss | 17.86 μM |
| TOX21_HSE_BLA_Agonist_ratio | Cervix | Human | 3297 | HSF1 | Gain | 59.42 μM |
| TOX21_p53_BLA_p2_ratio | Intestinal | Human | 7157 | TP53 | Gain | 73.08 μM |
| TOX21_p53_BLA_p3_ratio | Intestinal | Human | 7157 | TP53 | Gain | 73.78 μM |
| TOX21_p53_BLA_p5_ratio | Intestinal | Human | 7157 | TP53 | Gain | 76.43 μM |
| TOX21_HDAC_LUC_Antagonist | Colon | Human | 3065 | HDAC1 | Loss | 32.67 μM |
| TOX21_SHH_3T3_GLI3_LUC_Antagonist | Embryo | Mouse | 6469 | SHH | Loss | 21.09 μM |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.